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Abstract
Background
While prednisolone is commonly used to treat recent nerve function impairment (NFI) in lep-
rosy patients, the optimal treatment duration has not yet been established. In this “Treat-
ment of Early Neuropathy in Leprosy” (TENLEP) trial, we evaluated whether a 32-week
prednisolone course is more effective than a 20-week course in restoring and improving
nerve function.
Methods
In this multi-centre, triple-blind, randomized controlled trial, leprosy patients who had
recently developed clinical NFI (<6 months) were allocated to a prednisolone treatment regi-
men of either 20 weeks or 32 weeks. Prednisolone was started at either 45 or 60 mg/day,
depending on the patient’s body weight, and was then tapered. Throughout follow up, NFI
was assessed by voluntary muscle testing and monofilament testing. The primary outcome
was the proportion of patients with improved or restored nerve function at week 78. As sec-
ondary outcomes, we analysed improvements between baseline and week 78 on the Reac-
tion Severity Scale, the SALSA Scale and the Participation Scale. Serious Adverse Events
and the need for additional prednisolone treatment were monitored and reported.
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Results
We included 868 patients in the study, 429 in the 20-week arm and 439 in the 32-week arm.
At 78 weeks, the proportion of patients with improved or restored nerve function did not differ
significantly between the groups: 78.1% in the 20-week arm and 77.5% in the 32-week arm
(p = 0.821). Nor were there any differences in secondary outcomes, except for a significant
higher proportion of Serious Adverse Events in the longer treatment arm.
Conclusion
In our study, a 20-week course of prednisolone was as effective as a 32-week course in
improving and restoring recent clinical NFI in leprosy patients. Twenty weeks is therefore
the preferred initial treatment duration for leprosy neuropathy, after which likely only a minor-
ity of patients require further individualized treatment.
Author summary
Nerve damage is a common and severe consequence of leprosy, and it can lead to impair-
ment of sensory (sensibility) or motor (muscle) function of hand, feet and eyes. To pre-
vent that the nerve damage becomes permanent, it is essential that new damage is treated
in an early stage. Prednisolone, an immune suppressor, is the drug of choice. However,
the ideal treatment duration is unknown. In our study, we compared a prednisolone treat-
ment of 20 weeks with a longer treatment of 32 weeks. After the follow up period of 1.5
years, the percentage of patients with an improved or completely restored nerve function
was the same in the two treatment groups, namely 78%. We can conclude that the longer
treatment duration was not more effective, and that 20 weeks of prednisolone is sufficient
to treat early nerve damage in most patients. We also found that in 15% of the patients
neither one of the treatments was effective. For this specific group, more research needs to
be done to find if alternative medication or perhaps even longer prednisolone treatment
can be helpful.
Introduction
Leprosy is an infectious disease caused by Mycobacterium leprae. Since the introduction of
antibiotic multidrug treatment (MDT) in the 1980’s, the number of leprosy diagnoses has
decreased dramatically, and the disease was even declared eliminated as a public health prob-
lem at a global level in the year 2000 –i.e. less than 1 case per 10 000 inhabitants. Nevertheless,
in 2015 a total of 210 000 new leprosy patients were diagnosed worldwide [1].
A main complication of leprosy is neuropathy, which often causes sensory and motor nerve
function impairment (NFI). Untreated NFI can result in deformities of the hands and feet and
may also affect the eyes. NFI can develop before MDT has started, but it can also arise during
MDT and even several years after leprosy treatment has been completed [2,3]. The risk of
developing new NFI within two years of starting MDT can be as high as 65% [4].
To prevent disabilities and deformities in leprosy patients, it is very important to detect and
treat neuropathy in an early stage. Neuropathy is commonly treated with prednisolone [5], an
immune suppressor that reduces the body’s immune responses towards M. leprae and relieves
the pressure on the nerves by reducing inflammation and oedema [6,7].
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Although ideally prednisolone therapy is adjusted to individual needs and response, this is
not always feasible in field clinics, which often lack the treatment expertise of referral centres
[8]. In these situations, the WHO recommends a standardized prednisolone treatment for 12
weeks [9].
Even though observational studies suggest that prednisolone can improve nerve function in
60–70% of nerves [2, 10–12], this effect has never been established in randomized controlled
trials (RCT) [13]. There are indications, however, that a longer treatment duration may be
more effective than the WHO standardized treatment. In an RCT in India, type 1 reaction
(T1R) patients on a 20-week prednisolone course required less additional prednisolone than
patients on a 12-week course [14]. Further research is needed to establish the optimal prednis-
olone regimen specifically for leprosy patients with NFI.
For this reason, we designed a study entitled “Treatment of Early Neuropathy in Leprosy”
(TENLEP), comprising two RCTs aimed at determining how prednisolone treatment best can
prevent permanent NFI. In this paper we describe the results of the Clinical trial, in which we
evaluated whether a 32-week prednisolone course is more effective than a 20-week course in
restoring and improving recent clinical neuropathy (<6 months) [15].
Methods
The TENLEP study was a multicentre, triple blind parallel-group clinical trial, conducted in
six referral centres for leprosy in India, Nepal, Bangladesh and Indonesia. A more detailed
description of the TENLEP study can be found in the study protocol paper [15].
Ethics statement
Before trial initiation, approvals were obtained in each country from the appropriate ethical
review committees: in India from the Indian Council of Medical Research and the Ethics Com-
mittee of the Foundation for Medical Research, Mumbai (FMR/IEC/LEP.01b/2011); in Nepal
from the Nepal Health Research Council (Reg.no 14/2011); in Indonesia from the Komite
Etik Penelitian Kesehatan RSUD Dr. Soetomo Surabaya (100/Panke.KKE/V/2011); in Bangla-
desh from the Bangladesh Medical Research Council- National Research Ethics Committee
(BMRC/NREC/2010-2013/533). Written informed consent was taken from all patients, or
their parents in case the patient was under the age of 18 years. The trial was registered in the
Netherlands Trial Register (NTR2300) and in the Clinical Trials Registry India (CTRI/2011/
09/002022 and 23).
Patients
Leprosy patients between 15 and 60 years of age with any recent peripheral NFI (less than 6
months onset) were eligible for the trial. Leprosy diagnosis and classification assignment was
confirmed with physical exam by an experienced clinician, physiotherapist exam for neuropa-
thy and slit skin smear microscopy. Ridley-Jopling classification was clinically assigned except
in Anandaban hospital, where skin biopsy histopathology was additionally employed. NFI
was established with voluntary muscle testing (VMT) and/or monofilament testing (MFT).
Patients were excluded if they were pregnant, already receiving prednisolone treatment, suf-
fered from other conditions that may affect the peripheral nervous system, or presented with a
single skin lesion on the trunk as the only sign of leprosy. The sample size was calculated to be
able to detect ‘restored or improved’ nerve function in 70% of the intervention group, com-
pared to an assumed proportion of 60% in the control group. This one-tailed hypothesis, using
80% power, 5% significance and allowing for 20% loss to follow-up, lead to a sample size of
720 patients.
A study into the effectiveness of longer prednisolone treatment for leprosy neuropathy
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Treatment
Prednisolone dose started at 45 mg/day for patients with low weight (50 kg) and at 60 mg/
day for patients with high weight (>50 kg). The prednisolone dose was then slowly tapered
during the treatment period, maintaining a plateau of 20–35 mg/day for 20 weeks in the
32-week arm–depending on weight group. Total dosage and dose over time are previously
described [15]. To check the chemical composition of the prednisolone and placebo tablets, a
random selection of packages from both treatment groups was evaluated at the start of the trial
by the manufacturer (Rubicon), and by an independent Indian laboratory (Medibios Labora-
tories). After 20 months, the composition was checked again by the Royal Dutch Society of
Pharmacists (KNMP). Treatment adherence was checked every month either verbally or by
checking the medication package of the previous month.
Randomization and blinding
Patients were randomly allocated to either 20 or 32 weeks of oral prednisolone, using a sepa-
rate computer-generated blocked randomization sequence for each centre and weight group,
blinded within pre-set patient numbered packaging. Patients were kept blinded, as the tablets
appeared the same and treatment duration was kept equal by using placebo tablets. In addi-
tion, research staff and the statistician were kept blinded until all data analyses were per-
formed. The key to treatment allocation was only broken if a patient had a serious adverse
event (SAE) or required individualized treatment for a reaction or worsening NFI.
Assessments
In each centre, monofilament testing and voluntary muscle testing were carried out by two
trained assessors, except in the Indonesian centre where ten assessors have performed the
tests. Assessments at baseline generally showed good inter-tester reliability [16]. For every
patient, the sensory function of six nerves and the motor function of seven nerves were
assessed on both left and right body side (total of 26 assessments). Sensory function was tested
on three test-sites for each nerve, using a standard set of Semmes-Weinstein monofilaments,
with the 200mg filament representing the normal threshold for the hand, and the 2g filament
for the foot. For motor function assessment, the 0–5 Medical Research Council (MRC) scale
was used [17]. The exact test methods and sites are previously described [13]. When the total
monofilament score for a nerve was 3 or more, the sensory nerve function was considered
impaired. A motor nerve scoring less than 5 on the Medical Research Council scale was also
regarded as impaired. Follow-up assessments for VMT and MFT were carried out monthly
during the treatment period (up to week 32), and at week 52 and 78. At baseline and the end of
the study a Screening of Activity Limitation and Safety Awareness (SALSA) scale [18] and a
Participation (P) scale [19] were completed for each patient. In addition, reaction severity was
monitored with a Reaction Severity Scale (RSS) [20] at baseline, week 32, 52 and 78. When a
patient did not show up for their follow-up appointment, a telephone call or in some cases a
home visit was made in an effort to get the patient visit the clinic for assessments. When indi-
cated in advance, a patient was allowed to miss one assessment, and the medication was pro-
vided for eight weeks.
As previously described, if nerve function deteriorated or new reaction symptoms devel-
oped, the trial treatment was stopped and an individually modified treatment was provided
[15]. A decision tree was used to help clinicians decide whether or not patients should con-
tinue in the trial or receive individualized treatment in case of new NFI or reaction symptoms.
Once individualized treatment was warranted, it was up to the clinician to decide on further
patient management. The definition used to determine deteriorating MFT was: an increase of
A study into the effectiveness of longer prednisolone treatment for leprosy neuropathy
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6 points or more on the score per nerve since the last assessment, or an increase of 3 points or
more on the score per nerve that was confirmed on the consecutive visit. VMT deterioration
was defined as: a reduction in VMT score by two or more points or a reduction of 1 point on
two consecutive visits. Removal from the trial treatment due to reactions was based on new or
deteriorating reaction symptoms.
Patients who developed a serious adverse event (SAE) were removed from trial treatment
and provided with individualized care. For both deteriorating and SAE cases, data collection
continued up to the full 78 weeks.
Primary and secondary outcomes
The primary study outcome was the proportion of patients with restored or improved nerve
function (of all nerves) as measured by MFT and/or VMT at 78 weeks. Secondary outcomes
considered six variables: individual nerves, impairment counts, RSS, SALSA-scale and P-scale
scores between baseline and week 78, SAE’s between the intervention and control groups, and
the proportion of patients needing additional prednisolone with considering differences in
timing, dose and duration. Definitions for restoration, improvement and deterioration in
these respective categories for secondary and primary outcomes were as previously described
and are depicted in Table 1 [15].
Data analysis
Data were entered at each centre in an Access Database and then combined to be analysed in
Stata. Data were analysed according to the modified intention-to-treat principle: data of all
randomized patients who matched the inclusion criteria were analysed for week 78, whether
they had finished treatment or not, including all patients lost to follow-up. To handle missing
data of patients lost to follow-up, the last observation carried forward method was used. For
Table 1. Overview of primary and secondary outcomes.
Outcome Definitions
Primary
outcome
Proportion of patients with restored or improved nerve function Using a composite score.
Restored: all nerves back to normal function
Improved: more restored* and/or improved** nerves than unchanged
and/or deteriorated*** nerves
Unchanged: same number of nerves impaired
Deteriorated: more deteriorated nerves than improved and/or restored
nerves
Secondary
outcomes
1. Proportion of restored, improved, unchanged, deteriorated
and fully impaired nerves for each specific nerve–e.g. ulnar
nerve
For six sensory nerves and seven motor nerves
2. Count of impairments Per patient 26 nerves were assessed. Each impaired nerve adds 1
point to the total score
3. Improvement Reaction Severity Scale Improvement: reduction in RSS of 3 or more points on the total score,
or a reduction of 2 or more points on any individual item of the scale
4. Improvement in SALSA-scale and P-scale Improvement: classified in a better category (extreme, severe,
moderate, mild, none)
5. Proportion of patients with Serious Adverse Events
6. Proportion of patients needing additional steroids for
treatment of reaction or worsening NFI
* restored: back to normal function
** improved: decrease of 3 points for MFT or increase of 1 point for VMT
***: deteriorated: increase of 3 points for MFT or decrease 1 point for VMT
https://doi.org/10.1371/journal.pntd.0005952.t001
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patients who received additional prednisolone, the assessment recorded at the time when addi-
tional prednisolone was first prescribed was carried forward. Only nerves with new impair-
ments (<6 months) were included in the analyses. The primary and secondary outcomes were
analysed using a Chi-Square test. A difference between treatment groups was considered sig-
nificant when the p-value was < 0.05.
Results
Participants
A total of 875 leprosy patients were enrolled in the trial, of whom 432 were randomized to the
20-week arm and 443 to the 32-week arm. Patients were recruited between February 2012 and
October 2013, and the last follow-up data were collected in July 2015. The flow diagram in Fig
1 illustrates the number of patients followed up and the reasons for drop out. Seven of the
Fig 1. Flow diagram of number of patients enrolled, randomized, treated and followed-up.
https://doi.org/10.1371/journal.pntd.0005952.g001
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randomized patients were excluded in the final analyses: one patient who had missing baseline
MFT assessments and six patients who did not meet the inclusion criteria of having recent
NFI. The number included in the analyses reported here was therefore 868.
Baseline data
The intake and distribution of several patient characteristics per research centre are presented
in Table 2. Table 3 shows the baseline demographic and clinical characteristics of the total
patient group. Differences in demographic and clinical characteristics did not reach statistical
significance between the groups. At baseline, sensory function was more often impaired than
motor function: for both groups the median number of nerves with impaired sensory function
was 3, ranging from 0–12, while the median number of nerves with impaired motor function
was 1 (0–13). The proportions of sensory and motor impairment per nerve are shown in Fig 2.
Number analysed
Of the 868 patients enrolled in the study, the trial treatment period—the first 32 weeks—was
completed by 281 (65.5%) in the 20-week arm and 293 (66.7%) in the 32-week arm. Complete
follow-up data until week 78 were collected for 230 (82%) of those patients in the 20-week arm
and 219 (75%) patients in the 32-week arm (see Fig 1). At week 78, follow-up data were col-
lected for 229 additional patients who did not complete trial treatment due to new NFI, new or
recurrent reactions, SAEs or loss to follow-up. For the intention-to-treat analyses, the primary
and secondary outcomes were analysed using the data of all patients who met the inclusion cri-
teria (n = 868). A separate per protocol analysis was carried out including only patients who
had completed treatment (n = 574).
Primary outcome
The proportion of patients with restored or improved nerve function at week 78 was almost
similar in both groups: 78.1% in the 20-week arm and 77.5% in the 32-week arm (p = 0.821).
At week 32 and week 52, this outcome was not significantly different between the two groups
either. Fig 3 shows the proportion of patients in each category of improvement. In the 20-week
arm, more patients showed completely restored nerve function than in the 32-week arm,
23.5% against 18.7%. The per-protocol analysis, leaving out treatment non-compliers, resulted
Table 2. Intake per research centre.
Centre Number of
patients
Gender (%
female)
Mean age Low weight group
(%)
20-week arm
(%)
Anandaban Hospital
Kathmandu, Nepal
57 26% 36.7 37% 47%
Foundation for Medical Research
Mumbai, India
82 15% 31.8 34% 49%
JALMA institute of Leprosy & Other Mycobacterial
Diseases
Agra, India
230 17% 31.5 53% 50%
Lalgadh Leprosy Hospital and Services Centre
Dhanusha, Nepal
166 28% 34.3 45% 50%
Danish Bangladesh Leprosy Mission
Nilphamari, Bangladesh
232 22% 39.1 51% 50%
Dr. Soetomo Hospital
Surabaya and Madura, Indonesia
101 25% 31.9 46% 48%
https://doi.org/10.1371/journal.pntd.0005952.t002
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in an overall slightly higher proportion of patients with restored and improved nerves. How-
ever, again no significant difference was found between the groups: 81.9% in the 20-week arm
and 81.7% in the 32-week arm (p = 0.960).
Secondary outcomes
Table 4 presents the outcomes per nerve, for six sensory and seven motor nerves. The propor-
tion of restored and improved motor nerves was overall higher than for sensory nerves. The
sensory function of the radial, sural and posterior tibial nerves had the highest proportion of
improvement and restoration. The motor function of the ulnar and posterior tibial nerves
improved most between baseline and week 78. The median count of impairments at baseline
and at week 78 is shown in Table 5. 75.7% of the patients in the 20-week arm showed an
improvement in count of impairment, compared to 70.8% in the 32-week arm (p = 0.149).
Table 5 also presents the results of the Reaction Severity scale, the SALSA scale and the P-scale
for every assessment point. The proportion of patients with improved in RSS score at week 78
was higher in the 32-week arm (70%) than in the 20-week arm (65%), but this difference was
Table 3. Baseline demographics and clinical characteristics of the 868 patients.
20-week arm 32-week arm
(n = 429) (n = 439)
Gender (% female) 101 (23.4%) 90 (20.4%)
Age (mean ±SD) 34.7 (12.1) 34.3 (12.1)
Literate (%) 241 (56.5%) 247 (56.3%)
MB/PB (% MB) 339 (79.2%) 357 (81.0%)
RJ classification
TT 9 (2.1%) 20 (4.6%)
BT 212 (49.4%) 203 (46.2%)
BB 61 (14.2%) 55 (12.5%)
BL 67 (15.6%) 70 (16.0%)
LL 40 (9.3%) 51 (11.6%)
PN 40 (9.3%) 40 (9.1%)
Average smear (mean ±SD)
TT 0 (0) 0 (0)
BT 0.3 (0.8) 0.2 (0.8)
BB 0.3 (0.7) 0.6 (1.2)
BL 2.0 (1.5) 2.0 (1.7)
LL 3.0 (1.8) 3.2 (1.7)
PN 0.4 (0.8) 0 (0)
Disability grade
0 171 (39.9%) 165 (37.6%)
1 158 (36.8%) 176 (40.1%)
2 100 (23.3%) 98 (22.3%)
T1R
Mild 66 (15.4%) 59 (13.4%)
Severe 14 (3.3%) 24 (5.5%)
T2R
Mild 11 (2.6%) 14 (3.2%)
Severe 2 (0.5%) 6 (1.4%)
MB: Multibacillary; PB: Paucibacillary; RJ: Ridley-Jopling; T1R: Type 1 Reaction; T2R: Type 2 Reaction
https://doi.org/10.1371/journal.pntd.0005952.t003
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not statistically significant (p = 0.09). At 78 weeks, the day-to-day situation for patients had
barely improved: the scores of both SALSA and P-scale reduced slightly between baseline and
week 78. The change over time did not differ significantly between the two arms (p = 0.638 for
SALSA and p = 0.543 for P-scale).
Fig 2. Baseline impairments for sensory and motor nerves.
https://doi.org/10.1371/journal.pntd.0005952.g002
Fig 3. Percentage of patients with restored, improved, unchanged and deteriorated nerve function
impairment at week 78 as primary outcome.
https://doi.org/10.1371/journal.pntd.0005952.g003
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Additional prednisolone, to treat new or deteriorating NFI and reactions, was required in
68 (16%) patients in the 20-week arm and 65 (15%) patients in the 32-week arm. This differ-
ence was not statistically significant. Interestingly, the majority (38/68) of these patients in the
20-week arm needed additional prednisolone between week 21 and week 32, while in the
32-week arm additional prednisolone was given mostly between week 33 and 52 (56/65). In
the 32-week arm, the additional prednisolone given before week 32 was largely (78%) due to
reaction—with or without accompanying worsening of NFI, while the additional prednisolone
given after week 32 was more often for deteriorating NFI without reaction (55% of the cases
needing additional prednisone did not have other reaction symptoms). Fig 4 shows the time
until the first event requiring an additional prednisolone. The dose and duration of additional
prednisolone treatment did not significantly differ between the two groups.
When zooming in on the group of patients that needed additional prednisolone (indepen-
dent of treatment arm), it became apparent that their baseline characteristics differed from the
group that did not need additional prednisolone. Table 6 gives an overview of these character-
istics. Next to the presented variables, patients needing additional prednisolone during or after
Table 4. Outcomes per nerve at week 78.
n Normal Restored Improved Unchanged Deteriorated
SENSORY % % % % %
Trigeminal 20 weeks 858 97.4 1.5 - 0.9 0.1
32 weeks 878 98.2 1.4 - 0.1 0.3
Ulnar 20 weeks 830 60.2 17.1 9.3 5.4 8.0
32 weeks 850 55.3 17.8 11.9 5.7 9.4
Median 20 weeks 839 69.0 14.4 5.7 4.1 6.8
32 weeks 860 67.1 12.2 8.7 4.0 8.0
Radial 20 weeks 814 49.6 24.1 11.4 6.0 8.9
32 weeks 845 47.5 21.7 14.1 5.4 11.4
Posterior tibial* 20 weeks 810 51.4 17.0 11.0 9.9 10.7
32 weeks 839 46.6 16.6 16.2 11.1 9.5
Sural* 20 weeks 784 41.5 14.8 17.6 14.2 12.0
32 weeks 827 37.1 16.1 17.7 20.9 8.2
MOTOR n % % % % %
Eye closure 20 weeks 852 90.3 4.9 1.8 2.1 0.9
32 weeks 871 91.9 4.8 1.5 1.0 0.8
Ulnar 20 weeks 826 61.0 15.3 7.1 10.4 6.2
32 weeks 855 60.9 13.1 8.2 12.4 5.4
Median 20 weeks 850 84.5 8.1 0.6 2.7 4.1
32 weeks 870 84.6 8.3 1.3 3.2 2.6
Radial 20 weeks 856 95.7 3.0 0.1 0.2 0.9
32 weeks 877 95.4 2.9 0.1 0.6 1.0
Lateral popliteal (dorsiflexion foot) 20 weeks 850 90.5 5.9 1.1 1.7 0.9
32 weeks 871 89.8 5.9 0.8 2.3 1.3
Posterior tibial up 20 weeks 833 79.4 10.8 2.2 4.6 3.1
32 weeks 861 81.2 9.1 1.7 5.7 2.3
Posterior tibial down 20 weeks 826 77.2 11.6 0.4 5.8 5.0
32 weeks 860 76.5 12.9 0.4 6.9 3.4
*Difference between arms is statistically significant
https://doi.org/10.1371/journal.pntd.0005952.t004
A study into the effectiveness of longer prednisolone treatment for leprosy neuropathy
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005952 October 4, 2017 10 / 18
the trial period also showed significantly more often other reaction signs, i.e. inflamed and
raised skin lesions, peripheral oedema, nerve pain and tenderness.
Adverse events
There were seven deaths, three in the 20-week arm and four in the 32-week arm; but none
were related to trial treatment. SAE occurred in both groups, but were more often reported in
the intervention group: 12 cases (2.7%) in the 32-week arm and four cases (0.9%) in the
20-week arm [21]. This difference was statistically significant (p = 0.04). The main reported
SAE’s were hypertension (6), diabetes (6), and peptic ulcer (2): all commonly recognized side
effects associated with prednisolone treatment. Minor side effects were reported in 66% in the
32-week arm and 68% in the 20-week arm. Detailed results on adverse events will be reported
separately.
Additional analyses
We used logistic regression to assess the (univariate) association between clinical and demo-
graphic characteristics recorded at baseline and the primary outcome of improved or restored
nerve function. The five characteristics that demonstrated a significant correlation with the
primary outcome were weight group, body mass index (BMI), gender, WHO disability grade
and Eye Hand Foot (EHF) score. A patient with a higher BMI had higher odds on improved or
Table 5. Secondary outcomes: impairment, reaction severity scale, SALSA scale, P-scale.
20-week arm 32-week arm
n median n median Test statistic
(IQ range) (IQ range)
Count of impairments
Baseline sensory 429 3 (1–5) 439 3 (1–6) NS
Baseline motor 429 1 (1–3) 439 1 (1–3) NS
Total count baseline 429 4 (2–8) 439 4 (2–8) NS
Week 78 sensory 338 1 (0–4) 343 2 (0–4) NS
Week 78 motor 338 0 (0–2) 343 1 (0–2) P<0.05
Total count week 78 338 2 (0–5) 343 2 (1–6) NS
Difference total count baseline- week 78 338 2 (0–4) 343 2 (0–4) NS
Reaction Severity Scale
Baseline 426 4.5 (2–8.5) 438 5.5 (2.5–9.5) NS
Week 32 425 2 (0–5.5) 437 2.5 (0–6) NS
Week 52 427 2 (0–5.5) 437 2.5 (0–6) NS
Week 78 422 2 (0–5.5) 432 2 (0–6) NS
Difference total count baseline- week 78 420 2.5 (0–5) 432 3.5 (0–6) NS
SALSA scale
Baseline 402 23 (20–35) 412 24 (20–35) NS
Week 78 269 20 (20–24) 272 20.5 (20–26) NS
Difference baseline- week 78 269 0 (-1–3) 272 0 (-1–3) NS
P-Scale
Baseline 402 12.5 (1–21) 412 9 (0–20) NS
Week 78 269 5 (0–18) 273 6 (0–18) NS
Difference baseline- week 78 269 0 (-16–7) 273 0 (-18–5) NS
IQ: inter-quartile; NS: not significant
https://doi.org/10.1371/journal.pntd.0005952.t005
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restored nerve function at 78 weeks (OR = 1.09 (1.04–1.14)). The high weight group (>50 kg)
had a 1.43 (1.09–1.86) higher probability of a positive primary outcome than the low weight
group. Furthermore, women were 1.46 (1.06–2.10) times more likely to have a restored or
improved nerve function than men. The subgroup analysis also demonstrated that patients
having a grade 1 or 2 impairment at baseline were less likely to have restored or improved
nerve function at week 78 (OR Grade 1: 0.73 (0.54–0.98) and OR Grade 2: 0.19 (0.12–0.28)). A
Fig 4. Time until first event requiring additional prednisolone, i.e. a leprosy reaction and/or new NFI and/or
deteriorating NFI (n = 868).
https://doi.org/10.1371/journal.pntd.0005952.g004
Table 6. Overview of differences in baseline characteristics between the group that needed additional prednisolone and the group that did not
need additional prednisolone.
Additional prednisolone No additional prednisolone p-value
(n = 134) (n = 734)
WHO classification % MB 120 (89.6%) 576 (78.5%) 0.003
Ridley-Jopling <0.001
classification TT 2 (1.5%) 27 (3.7%)
BT 61 (45.5%) 354 (48.2%)
BB 10 (7.5%) 106 (14.4%)
BL 32 (23.9%) 105 (14.3%)
LL 23 (17.2%) 68 (9.3%)
PN 6 (4.5%) 74 (10.1%)
Skin smear (BI) Mean 1.4 0.7 <0.001
Positive 60 (44.8%) 157 (21.4%) <0.001
Eye-hand-foot score Mean 1.9 1.5 0.014
Positive 94 (70.2%) 438 (59.7%) 0.022
Type 1 reaction Positive 44 (32.8%) 119 (16.2%) <0.001
Type 2 reaction Positive 10 (7.2%) 22 (3.0%) 0.011
Weight group % high weight 82 (61.2%) 375 (51.1%) 0.031
BMI Mean 20.4 19.8 0.024
https://doi.org/10.1371/journal.pntd.0005952.t006
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higher EHF score also reduced the odds of a good outcome (OR: 0.73 (0.67–0.80). The follow-
ing baseline characteristics had no influence on improved nerve function: WHO classification,
Ridley-Jopling classification, BI (skin smear) and the presence or absence of severe Type 1 or
Type 2 reaction.
Using a Cox Proportional Hazard model, we assessed whether there was a trend across the
entire duration of follow up regarding primary outcome -i.e. not limited to 32, 52 and 78
weeks. The conclusion from this analysis was similar to what has been described above, there
was no effect of treatment arm on primary outcome.
Discussion
In both treatment arms in our study, a large majority (78%) of patients showed improvement
and restoration of nerve function, indicating that 20-week prednisolone treatment is sufficient
for most patients. However, around 15% of the patients required individualized further treat-
ment because of reactions or deteriorating NFI. Notably, the proportion of patients needing
additional prednisolone was similar in both groups (15% and 16%), and the duration and dose
of the additional prednisolone treatment did not differ either. However, we did see a difference
in timing of the need for additional prednisolone. New NFI and reactions were primarily
reported in the first few weeks after prednisolone treatment had ended, thus after 20 weeks
and 32 weeks respectively for the control and intervention arm. A similar rebound effect was
observed in the Trials in Prevention of Disability (TRIPOD) study and in the study of Rao
et al. [14,22]. The longer prednisolone treatment in our study seems to merely postpone the
immune response in some patients.
The roughly 15% of patients that required additional prednisolone differed at baseline from
the group that did not need extra prednisolone. This former group had significantly more MB
patients, mainly BL and LL, higher average skin smear, higher EHF score, had T1R and T2R
more often at baseline and showed more often increased signs of reaction, i.e. inflamed and
raised skin lesions, peripheral oedema, nerve pain and tenderness. Further studies of an even
longer prednisolone course than assessed in this study might be beneficial for these higher risk
patients, as it seems that the immune response against dead M. leprae bacilli is too persistent to
be permanently suppressed by a 32-week prednisolone course [23,24]. At present, however,
our results reinforce that 20 weeks tapered prednisolone with an extended higher dose plateau
is sufficient treatment for the majority of recent leprosy neuropathy cases, while extended indi-
vidualized treatment will be needed for some patients, which may be associated with com-
monly recognized risk factors for complications.
Women overall had a better response to prednisolone then men. This was unexpected as
previous studies show that women generally have longer delay in presenting with leprosy and
may then have more severe NFI at time of diagnosis with less chance for recovery [25–27].
Though, in our study we only included patients with a delay of less than 6 months and there-
fore a pre-selection of women with recent NFI was made.
The group of patients needing additional prednisolone had significantly more often certain
clinical baseline characteristics that are frequently associated with reduced outcomes, such as
high BI, MB classification and reactions. When analysing the correlation between baseline
characteristics and the primary outcome, i.e. improved/recovered vs. unchanged/deteriorated
NFI, we had expected that patients with deteriorated NFI would also have significantly more
often a high BI, MB classification and reactions at baseline. This was not the case, however.
One explanation may be that the group of ‘unchanged’ patients diluted the group of patients
with a deterioration, and made the association between these specific baseline characteristics
and primary outcome less strong.
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The mechanisms behind nerve damage in leprosy are generally not well understood and
challenging to study. Nerve biopsies can give some insight in the pathophysiology of neuropa-
thy, but are limited to a single point in time and do not provide information about the onset or
further development of impairment [23]. Several mechanisms are described in literature
though. In vitro, demyelination has been shown to occur when M. leprae invades the Schwann
cells [28–30]. This process can take place in an early stage, when the immune system has not
been activated yet. Secondary immune responses likely play a role via inflammatory cytokines
[31–34] and T-cells [35–38], leading to demyelination or damaging of Schwann cells. Last,
mechanical effects such as oedema and ischemia [23,39] can lead to axonal loss. Nerve regener-
ation can occur after the inflammation is controlled; however, the duration of the inflamma-
tion and nerve scarring may influence outcome [7, 39]. As a strong immunomodulator,
prednisolone can impact secondary responses to reduce the inflammation, reducing oedema
and scar formation [7]; thereby, providing time and space for nerve regeneration to occur if
applied within <6 months of symptoms [2,8,40, 41]. When the delay in prednisolone treat-
ment is too long (>6 months), the damage to the nerve is considered to be irreversible. From
previous studies [5,42], it seems that NFI of shorter onset duration prior to treatment has bet-
ter chances on improvement.
Observational studies in leprosy neuropathy have shown that prednisolone improves nerve
function [2,10–12]. Although prednisolone is generally considered an important drug for
improving NFI, it is not known by what mechanisms or to what extent prednisolone is respon-
sible for the reported improvements, such as in placebo controlled randomized controlled
trials like the TRIPOD studies [22,43]. Several studies have also indicated that a high propor-
tion of patients (33–75%) experience spontaneous nerve function improvement even if left
untreated, depending on the severity of NFI and type of nerve [22,44–46]. Even in 51% of pla-
cebo patients with old NFI (> 6 months of symptoms) improvement can be demonstrated
without prednisolone treatment [45]. A placebo-controlled RCT could be an important next
step to investigate the actual effect of prednisolone on the treatment of recent NFI. Alternatives
for prednisolone should continue to be sought, as so far no treatments have been proven effec-
tive. For example, azathioprine and cyclosporine, immunosuppressants used to treat reactions,
show only limited effect in studies inclusive of but not specifically for NFI [46–48]. Nerve
decompression, a surgical method to relieve severe inflammatory pressure, is sometimes used
to improve ongoing neuropathy in leprosy; however, controlled randomized trial evidence on
the effectiveness of this method is lacking as well [49].
The strongest point of our study is the multi-centre, multi-country design which enabled
representative sampling across leprosy demographics in South East Asia, where the bulk of
global leprosy cases are diagnosed. This RCT was unique in maintaining a middle plateau for a
longer time with a relatively high dose of prednisolone and demonstrated that a 20-week treat-
ment was sufficient for the majority of recent neuropathy cases. This RCT was also able to
demonstrate that baseline BMI of the patient was directly related to outcomes. This highlights
the practical and clinical relevance for contextual realities, such as extreme poverty and malnu-
trition present within some leprosy-affected populations [50–52]. Such issues can represent
individual complications for health and healing during a neuropathy episode.
At the conclusion of the study, three limitations became apparent. At the 78-week time
point, only 72% of the patients in the 20-week arm and 78% of the patients in the 32-week arm
provided data, exceeding the Evidence Based Medicine cut off of 20%, leading to a loss of valid-
ity [53]. In addition, treatment data was absent at other time points due to SAE, the need for
additional prednisolone or temporary loss-to-follow up. To limit potential bias related to non-
random loss of patients, data was analysed according to the intention to treat principle, using
the last observation carried forward approach. By using this approach, the results of this study
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are likely conservative with the actual improving effect of prednisolone on NFI possibly even
larger. A second limitation is that the duration of NFI prior to intake was self-reported, which
may have allowed recruitment of patients with previous symptoms beyond the 6 month cut-
off for inclusion and who were, therefore, less likely to demonstrate nerve improvement with
treatment [5,41]. The third limitation is that Ridley-Jopling classifications were based on clini-
cal aspects only, except for one centre that performed histopathology. The results of the logistic
regression to evaluate the effect of RJ classification on the final result should therefore be inter-
preted with care.
We conclude that a 20-week course is sufficient to improve nerve function in 78% of
patients with recent NFI. Future studies should focus on improved regimens or alternative
treatments, as approximately 15% of patients with recent NFI require additional prednisolone.
Moreover, alternative therapies could potentially reduce risks for developing steroid-depen-
dency and other long term treatment side effects. Secondly, it is important to better unravel
the pathophysiology of nerve function impairment and to study the actual effect of predniso-
lone on immune function as it relates to NFI. Understanding the mechanisms behind NFI
could lead to alternative, more effective solutions for the treatment of NFI and the prevention
of irreversible impairments and subsequent disabilities.
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